Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hau, P.
Right arrow Articles by Bogdahn, U.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hau, P.
Right arrow Articles by Bogdahn, U.
NEUROLOGY 2007;68:688-690
© 2007 American Academy of Neurology

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

P. Hau, MD, D. Koch, MD, T. Hundsberger, MD, E. Marg, MD, B. Bauer, MD, R. Rudolph, MD, M. Rauch, MD, A. Brenner, MD, P. Rieckmann, MD, J. Schuth, MD, T. Jauch, RN, H. Koch, MD, PhD and U. Bogdahn, MD

From the Klinik und Poliklinik für Neurologie der Universität Regensburg im Bezirksklinikum (P.H., T.J., H.K., U.B.), Universitätsstraße 84, Klinik und Poliklinik für Neurochirurgie (D.K.), Universität Mainz, Langenbeckstrasse 1, Klinik und Poliklinik für Neurologie (T.H.), Universität Mainz, Langenbeckstrasse 1, Landesklinik Brandenburg (E.M.), Klinik für Neurologie, Anton-Saekow-Allee, Klinikum Neubrandenburg (B.B.), Abteilung für Neurologie, Salvadore-Allende-Strasse 30, Facharztpraxis für Internistische Onkologie (R.R.), Kettwiger Strasse 64, Essen, Krankenanstalten Gilead (M.R.), Abteilung für Neurologie, Burgsteig 13, Bielefeld, Werner-Forßmann-Krankenhaus (A.B.), Abteilung für Neurochirurgie, Rudolf-Breitscheid-Strasse 100, Eberswalde, Klinikum der Universität Würzburg (P.R.), Klinik für Neurologie, Josef-Schneider-Strasse 11, Würzburg, Germany, and essex pharma GmbH (J.S.), Thomas-Dehler-Straße 27, München, Germany.

Address correspondence and reprint requests to Dr. P. Hau, Department of Neurology, District Medical Center, University of Regensburg, Universitätsstraße 84, 93053 Regensburg, Germany; e-mail: peter.hau{at}medbo.de

We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.

Presented in abstract form at the 2005 EANO VI meeting in Edinburgh, UK.

Disclosure: Peter Hau and Ulrich Bogdahn have received an educational grant from Schering-Plough for a basic science research project using temozolomide, which is not connected to the data reported in this article.

Received May 17, 2006. Accepted in final form October 30, 2006.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.